The production of liquid short-chain chlorinated paraffins (SCCP) was banned back in 1995. Since they are not water soluble, instead they form micro-droplets and accumulate in organic material. This bioaccumulation can also occur inside the human body, and chlorinated paraffins are considered carcinogenic. Even though they are no longer used, they can still pose problems during demolition work many years later. The EU has classified SCCPs as strongly toxic to aquatic environments.

The “standstill” transition period begins as the Withdrawal Agreement clears the final hurdle.

Three-and-a-half years since the Brexit vote, the UK has left the EU – with a deal. There was no late drama as the European Parliament approved the Withdrawal Agreement by 621 votes to 49.

The UK now enters a “transition period.” Although the UK will have no MEPs, no Commissioner, and no seat at the EU Council; EU law will continue to apply in the UK. And that means companies can continue UK batch release testing and qualified person (QP) certification; marketing authorization (MA) holders and QPs, and QPPVs can continue to be based in the UK and access EU markets; manufacturing and distribution licences will continue to be recognized by the EU and vice versa, as will inspections; and UK-based firms can continue to apply for MAs via either the centralized or decentralized procedure (1) * published in the Medicine Maker on 11th of February 2020

Hamburg/Turnhout, Januar 31 st , 2020. The GBA Group is strengthening its European network in the field of food analysis. With the acquisition of the leading food laboratory in the Belgian market, Lavetan NV, the GBA Group continues on the path to support customers outside of Germany with expertise and high-quality service. The advantageous location of Lavetan in Turnhout, near the important transshipment ports in Antwerp and Rotterdam, provides the GBA Group access to strategically important markets in Belgium and the Netherlands.

Medikamente. Import, Export und Herstellung von Arzneimittelnin der EU stehen im Fokus von ABF Pharmaceutical Services.

Gerade rechtzeitig zum Brexit hat die 2004 in Wien gegründete ABF Pharmaceutical Services (GBA Group Pharma), der einzige internationale Komplettdienstleister für Import, Export und Herstellung von Medikamenten in klinischen Studien (Prüfware) in Österreich, ihre Kapazitäten am neuen Standort in Wien 23 mehr als verdoppelt. Und das nicht nur aufgrund der wachsenden Nachfrage der internationalen Pharma- und Biotech-Branche, sondern auch um der Rolle eines Brexit Safe Havens gerecht zu werden.

Hamburg/Turnhout, Januar 31 st , 2020. The GBA Group is strengthening its European network in the field of food analysis. With the acquisition of the leading food laboratory in the Belgian market, Lavetan NV, the GBA Group continues on the path to support customers outside of Germany with expertise and high-quality service. The advantageous location of Lavetan in Turnhout, near the important transshipment ports in Antwerp and Rotterdam, provides the GBA Group access to strategically important markets in Belgium and the Netherlands.